Results 71 to 80 of about 37,077 (282)

Intein mediated high throughput screening for bispecific antibodies

mAbs, 2020
Bispecific antibodies comprise extremely diverse architectures enabling complex modes of action, such as effector cell recruitment or conditional target modulation via dual targeting, not conveyed by monospecific antibodies.
Tim Hofmann, Johannes Schmidt, Elke Ciesielski, Stefan Becker, Thomas Rysiok, Mark Schütte, Lars Toleikis, Harald Kolmar, Achim Doerner   +8 more
doaj   +1 more source

Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of ‘Almost Natural’ Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection

Frontiers in Immunology, 2022
A subset of antibodies found in cattle comprises ultralong CDR-H3 regions of up to 70 amino acids. Interestingly, this type of immunoglobulin usually pairs with the single germline VL gene, V30 that is typically very conserved in sequence.
Daniel Klewinghaus, Lukas Pekar, Paul Arras, Simon Krah, Bernhard Valldorf, Harald Kolmar, Stefan Zielonka   +6 more
doaj   +1 more source

Core Fucosylation Represses SMURF1‐Dependent Degradation of CD47 to Promote Tumor Immune Evasion

Advanced Science, EarlyView.
FUT8‐mediated core fucosylation of CD47 at N111 blocks SMURF1 binding and reduces CD47 ubiquitination and degradation. Blocking N111 glycosylation reduces CD47 expression and promotes macrophage phagocytosis of tumor cells. Furthermore, ablating CD47 core fucosylation boosts CD103+ dendritic cells (DCs) infiltration, increases natural killer (NK) cell ...
Yuting Cao, Siyuan Chai, Mingyang Li, Xiaoming Chen, Jiating Hu, Bingyi Lin, Liming Wu, Wen Yi, Qiang Zhu   +8 more
wiley   +1 more source

Prodrug-based bispecific antibodies for cancer therapy: advances and future directions

Frontiers in Immunology
Bispecific antibodies represent an innovative paradigm in cancer therapy, offering broader therapeutic potential compared to conventional monoclonal antibodies.
Zhijuan Ai, Zhijuan Ai, Bing Wang, Yunlong Song, Panpan Cheng, Xinlin Liu, Xinlin Liu, Peng Sun   +7 more
doaj   +1 more source

Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?

Antibodies, 2015
As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies ...
Joanie Del Bano, Patrick Chames, Daniel Baty, Brigitte Kerfelec   +3 more
doaj   +1 more source

EXTH-08. REPLACEMENT OF MICROGLIA BY BRAIN-ENGRAFTED MACROPHAGES PREVENTS MEMORY DEFICITS AFTER THERAPEUTIC WHOLE-BRAIN IRRADIATION [PDF]

, 2019
Microglia have a distinct origin compared to blood circulating myeloid cells. Under normal physiological conditions, microglia are maintained by self-renewal, independent of hematopoietic progenitors. Following genetic or pharmacologic depletion, newborn
Boosalis, Zoe, Chen, David, Feng, Xi, Gupta, Nalin, Gupta, Sonali, Liu, Sharon, Rosi, Susanna   +6 more
core   +1 more source

Structural insights and biomedical potential of IgNAR scaffolds from sharks [PDF]

, 2014
Peer reviewedPublisher ...
Barelle, Caroline, Empting, Martin, Grzeschik, Julius, Kolmar, Harald, Könning, Doreen, Zielonka, Stefan   +5 more
core   +1 more source

Chemical generation of bispecific antibodies [PDF]

Proceedings of the National Academy of Sciences, 2010
Bispecific antibodies (BsAbs) are regarded as promising therapeutic agents due to their ability to simultaneously bind two different antigens. Several bispecific modalities have been developed, but their utility is limited due to problems with stability and manufacturing complexity.
Venkata R, Doppalapudi, Jie, Huang, Dingguo, Liu, Ping, Jin, Bin, Liu, Lingna, Li, Joel, Desharnais, Crystal, Hagen, Nancy J, Levin, Michael J, Shields, Michelle, Parish, Robert E, Murphy, Joselyn, Del Rosario, Bryan D, Oates, Jing-Yu, Lai, Marla J, Matin, Zemeda, Ainekulu, Abhijit, Bhat, Curt W, Bradshaw, Gary, Woodnutt, Richard A, Lerner, Rodney W, Lappe   +21 more
openaire   +2 more sources

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies

iScience
Summary: A current challenge is the emergence of SARS-CoV-2 variants, such as BQ.1.1 and XBB.1.5, that can evade immune defenses, thereby limiting antibody drug effectiveness. Emergency-use antibody drugs, including the widely effective bebtelovimab, are
Tetsuya Inoue, Yuichiro Yamamoto, Kaoru Sato, Yuko Okemoto-Nakamura, Yoshimi Shimizu, Motohiko Ogawa, Taishi Onodera, Yoshimasa Takahashi, Takaji Wakita, Mika K. Kaneko, Masayoshi Fukasawa, Yukinari Kato, Kohji Noguchi   +12 more
doaj   +1 more source